Crispr Therapeut Financials
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Crispr Therapeut has an operating margin of 1898.8%, meaning the company retains $1899 of operating profit per $100 of revenue. This strong profitability earns a score of 100/100, reflecting efficient cost management and pricing power. This is up from -1250.4% the prior year.
Crispr Therapeut's revenue declined 99.9% year-over-year, from $37.3M to $35K. This contraction results in a growth score of 0/100.
Crispr Therapeut carries a low D/E ratio of 0.18, meaning only $0.18 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 13.32, Crispr Therapeut holds $13.32 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Crispr Therapeut converts 983.1% of revenue into free cash flow ($344K). This strong cash generation earns a score of 100/100.
Crispr Therapeut earns a strong 30.3% return on equity (ROE), meaning it generates $30 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 100/100.
Crispr Therapeut scores 8902.69, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($5.1B) relative to total liabilities ($343K). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Crispr Therapeut passes 3 of 9 financial strength tests. 3 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, Crispr Therapeut generates $0.59 in operating cash flow ($345K OCF vs $582K net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.
This page shows Crispr Therapeut (CRSP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Crispr Therapeut generated $35K in revenue in fiscal year 2025. This represents a decrease of 99.9% from the prior year.
Crispr Therapeut's EBITDA was $684K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 100.2% from the prior year.
Crispr Therapeut generated $344K in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 100.2% from the prior year.
Crispr Therapeut reported $582K in net income in fiscal year 2025. This represents an increase of 100.2% from the prior year.
Crispr Therapeut earned $6.47 per diluted share (EPS) in fiscal year 2025. This represents an increase of 249.1% from the prior year.
Crispr Therapeut held $348K in cash against $0 in long-term debt as of fiscal year 2025.
Crispr Therapeut had 96M shares outstanding in fiscal year 2025. This represents an increase of 11.9% from the prior year.
Crispr Therapeut's operating margin was 1898.8% in fiscal year 2025, reflecting core business profitability. This is up 3149.2 percentage points from the prior year.
Crispr Therapeut's net profit margin was 1661.7% in fiscal year 2025, showing the share of revenue converted to profit. This is up 2643.3 percentage points from the prior year.
Crispr Therapeut's ROE was 30.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Crispr Therapeut invested $285K in research and development in fiscal year 2025. This represents a decrease of 99.9% from the prior year.
Crispr Therapeut invested $914 in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 100.0% from the prior year.
CRSP Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $864K-2.8% | $889K-0.3% | $892K+3.1% | $865K-97.6% | $35.7M+5828.7% | $602K+16.4% | $517K+2.6% | $504K |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $83.5M+41.8% | $58.9M-15.7% | $69.9M-3.6% | $72.5M+1.0% | $71.7M-12.7% | $82.2M+2.5% | $80.2M+5.2% | $76.2M |
| SG&A Expenses | $18.4M+8.7% | $16.9M-10.5% | $18.9M-2.0% | $19.3M+6.5% | $18.1M+4.0% | $17.4M-10.6% | $19.5M+8.5% | $18.0M |
| Operating Income | -$154.8M-17.2% | -$132.1M+42.4% | -$229.3M-54.5% | -$148.4M-129.8% | -$64.6M+41.4% | -$110.1M+27.2% | -$151.3M-7.6% | -$140.6M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $614K-0.8% | $619K-52.1% | $1.3M+16.5% | $1.1M+58.4% | $700K-20.1% | $876K-31.9% | $1.3M+77.8% | $724K |
| Net Income | -$130.6M-22.7% | -$106.4M+49.0% | -$208.5M-53.3% | -$136.0M-264.5% | -$37.3M+56.6% | -$85.9M+32.0% | -$126.4M-8.4% | -$116.6M |
| EPS (Diluted) | $-1.32-12.8% | $-1.17+51.3% | $-2.40-51.9% | $-1.58-285.4% | $-0.41+59.4% | $-1.01+32.2% | $-1.49-4.2% | $-1.43 |
CRSP Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $2.3B+0.9% | $2.2B+10.6% | $2.0B-6.3% | $2.2B-3.4% | $2.2B-0.6% | $2.3B-3.6% | $2.3B-4.1% | $2.4B |
| Current Assets | $2.0B+2.9% | $1.9B+11.3% | $1.7B-7.2% | $1.9B-3.6% | $1.9B-0.3% | $1.9B-3.3% | $2.0B-5.2% | $2.1B |
| Cash & Equivalents | $347.6M+21.3% | $286.5M+48.0% | $193.6M-17.7% | $235.2M-21.1% | $298.3M+32.2% | $225.7M-53.4% | $484.5M-31.5% | $707.4M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $0 | $0 | $0 | $0-100.0% | $25.0M | $0 | $0 | $0 |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $343.4M+4.3% | $329.3M+3.4% | $318.6M-5.4% | $336.9M+8.7% | $310.0M-2.1% | $316.5M-11.8% | $358.9M+1.1% | $355.1M |
| Current Liabilities | $149.1M+25.4% | $119.0M+14.0% | $104.4M-12.6% | $119.4M+36.1% | $87.8M-2.3% | $89.8M-29.7% | $127.8M+7.4% | $119.0M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $1.9B+0.3% | $1.9B+12.0% | $1.7B-6.5% | $1.8B-5.3% | $1.9B-0.4% | $1.9B-2.1% | $2.0B-4.9% | $2.1B |
| Retained Earnings | -$1.9B-7.2% | -$1.8B-6.2% | -$1.7B-13.9% | -$1.5B-10.0% | -$1.4B-2.8% | -$1.3B-6.9% | -$1.2B-11.3% | -$1.1B |
CRSP Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$92.6M-9.4% | -$84.6M+25.7% | -$113.9M-111.1% | -$53.9M-7.8% | -$50.0M+53.2% | -$106.9M-11.9% | -$95.6M-187.1% | $109.8M |
| Capital Expenditures | $517K+598.6% | $74K-36.8% | $117K-43.2% | $206K-18.9% | $254K+16.0% | $219K-69.0% | $707K-1.9% | $721K |
| Free Cash Flow | -$93.1M-9.9% | -$84.7M+25.7% | -$114.0M-110.5% | -$54.2M-7.7% | -$50.3M+53.1% | -$107.1M-11.3% | -$96.3M-188.3% | $109.0M |
| Investing Cash Flow | $37.2M+131.2% | -$119.2M-270.4% | $70.0M+454.2% | -$19.8M-118.7% | $105.8M+165.5% | -$161.6M-27.3% | -$126.9M-29.8% | -$97.8M |
| Financing Cash Flow | $116.4M-60.8% | $296.8M+13042.9% | $2.3M-78.7% | $10.6M-37.3% | $16.9M+75.1% | $9.6M+2168.7% | -$466K-100.2% | $305.9M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
CRSP Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -17912.5%-3057.7pp | -14854.8%+10854.2pp | -25709.0%-8550.1pp | -17158.8%-16977.9pp | -181.0%+18113.1pp | -18294.0%+10963.2pp | -29257.3%-1363.0pp | -27894.3% |
| Net Margin | -15117.3%-3144.1pp | -11973.1%+11406.8pp | -23379.9%-7657.8pp | -15722.1%-15617.5pp | -104.5%+14171.5pp | -14276.1%+10174.2pp | -24450.3%-1317.2pp | -23133.1% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -5.8%-1.0pp | -4.7%+5.5pp | -10.3%-4.0pp | -6.3%-4.6pp | -1.7%+2.2pp | -3.8%+1.6pp | -5.4%-0.6pp | -4.8% |
| Current Ratio | 13.32-2.9 | 16.22-0.4 | 16.61+1.0 | 15.64-6.4 | 22.07+0.4 | 21.64+5.9 | 15.73-2.1 | 17.81 |
| Debt-to-Equity | 0.180.0 | 0.17-0.0 | 0.190.0 | 0.18+0.0 | 0.160.0 | 0.16-0.0 | 0.18+0.0 | 0.17 |
| FCF Margin | -10772.0%-1243.5pp | -9528.5%+3251.5pp | -12779.9%-6519.5pp | -6260.5%-6119.6pp | -140.9%+17655.1pp | -17796.0%+828.5pp | -18624.6%-40257.7pp | 21633.1% |
Similar Companies
Frequently Asked Questions
What is Crispr Therapeut's annual revenue?
Crispr Therapeut (CRSP) reported $35K in total revenue for fiscal year 2025. This represents a -99.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Crispr Therapeut's revenue growing?
Crispr Therapeut (CRSP) revenue declined by 99.9% year-over-year, from $37.3M to $35K in fiscal year 2025.
Is Crispr Therapeut profitable?
Yes, Crispr Therapeut (CRSP) reported a net income of $582K in fiscal year 2025, with a net profit margin of 1661.7%.
What is Crispr Therapeut's earnings per share (EPS)?
Crispr Therapeut (CRSP) reported diluted earnings per share of $6.47 for fiscal year 2025. This represents a 249.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Crispr Therapeut's EBITDA?
Crispr Therapeut (CRSP) had EBITDA of $684K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Crispr Therapeut's operating margin?
Crispr Therapeut (CRSP) had an operating margin of 1898.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Crispr Therapeut's net profit margin?
Crispr Therapeut (CRSP) had a net profit margin of 1661.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Crispr Therapeut's return on equity (ROE)?
Crispr Therapeut (CRSP) has a return on equity of 30.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Crispr Therapeut's free cash flow?
Crispr Therapeut (CRSP) generated $344K in free cash flow during fiscal year 2025. This represents a 100.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Crispr Therapeut's operating cash flow?
Crispr Therapeut (CRSP) generated $345K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Crispr Therapeut's total assets?
Crispr Therapeut (CRSP) had $2.3M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Crispr Therapeut's capital expenditures?
Crispr Therapeut (CRSP) invested $914 in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Crispr Therapeut spend on research and development?
Crispr Therapeut (CRSP) invested $285K in research and development during fiscal year 2025.
How many shares does Crispr Therapeut have outstanding?
Crispr Therapeut (CRSP) had 96M shares outstanding as of fiscal year 2025.
What is Crispr Therapeut's current ratio?
Crispr Therapeut (CRSP) had a current ratio of 13.32 as of fiscal year 2025, which is generally considered healthy.
What is Crispr Therapeut's debt-to-equity ratio?
Crispr Therapeut (CRSP) had a debt-to-equity ratio of 0.18 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Crispr Therapeut's return on assets (ROA)?
Crispr Therapeut (CRSP) had a return on assets of 25.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Crispr Therapeut's Altman Z-Score?
Crispr Therapeut (CRSP) has an Altman Z-Score of 8902.69, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Crispr Therapeut's Piotroski F-Score?
Crispr Therapeut (CRSP) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Crispr Therapeut's earnings high quality?
Crispr Therapeut (CRSP) has an earnings quality ratio of 0.59x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Crispr Therapeut?
Crispr Therapeut (CRSP) scores 83 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.